Brief: Cogent Biosciences Q3 EPS USD -0.64
12/11/2024 13:00
Nov 12 (Reuters) - Cogent Biosciences Q3 income from operations USD -75.414 million. * Q3 operating expenses USD 75.414 million * Q3 net income USD -70.634 million
Recent news on Cogent Biosciences
See all newsBrief: Cogent Biosciences - Enters Commercial Supply Agreement With Hovione On Sept 1, 2026 - SEC Filing
Brief: Cogent Biosciences - May Offer Up To $400 Million In Common Stock Through Guggenheim Securities
Cogent Biosciences Q2 net loss widens on higher expenses
Brief: Cogent Biosciences Q2 Net Income USD -96.405 Million
U.S. STOCKS ON THE MOVE-Snowflake, Best Buy, Kohl's